There could be another vaccine option in the U.S. in the not-so-distant future.
AstraZeneca said its most-recent large-scale study found no safety concerns related to the vaccine including blood clots, which had been a concern initially.
It has not yet been approved in the U.S. When it is, though, this will mark the fourth vaccine made available in the U.S.
How effective is it? Experts say around 79%, which puts it in-between effectiveness of the other available vaccines. Like the Moderna and Pfizer vaccines, though, two doses will be required.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]